kabutan
N225

68,713.80

+0.59%

TOPIX

4,197.20

+0.51%

USDJPY

159.29

-0.15%

KAKEN PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 53%

Fri Sep 26, 2025 4:00 pm JST Revision

4521 KAKEN PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Guidance Update Report

KAKEN PHARMACEUTICAL CO.,LTD. <4521> [TSE Prime] announced a performance revision after the market closed on September 26th (16:00). The consolidated ordinary profit forecast for the fiscal year ending March 2026 has decreased 53.3%, from the previous forecast of 6.00 billion yen to 2.80 billion yen (compared to 21.2 billion yen in the previous period), leading to an increase in the profit decline rate from 71.8% to 86.8%.

Furthermore, The company continued to decline to disclose its earnings forecast for April to September (first half).

Kabutan News

Guidance Update

Full Year Update
Fiscal Year Revenue Operating
Profit
Ordinary
Profit
Net
Profit
Adj.
EPS
Adj.
Dividend
Announce Accounting
Standards
Mar, 2026 Prev 88,000M 5,200M 6,000M 3,400M 89.8 190 May 12, 2025 J-GAAP
Mar, 2026 New 86,300M 2,100M 2,800M 2,300M 60.7 190 Sep 26, 2025 J-GAAP
Revision Rate -1.9% -59.6% -53.3% -32.4% -32.3%

Current Period Guidance

First Half Results
Fiscal Year Revenue Operating
Profit
Ordinary
Profit
Net
Profit
Adj.
EPS
Adj.
Dividend
Announce Accounting
Standards
Apr - Sep, 2024
51,372M 19,579M 19,823M 14,286M 377.2 115 Nov 8, 2024 J-GAAP
Guidance
Apr - Sep, 2025
95 May 12, 2025 J-GAAP
YoY
Current Period Guidance
Fiscal Year Revenue Operating
Profit
Ordinary
Profit
Net
Profit
Adj.
EPS
Adj.
Dividend
Announce Accounting
Standards
Mar, 2024
72,044M 9,513M 9,951M 8,025M 212.7 150 May 14, 2024 J-GAAP
Mar, 2025
94,035M 21,034M 21,279M 13,945M 365.4 190 May 12, 2025 J-GAAP
Guidance
Mar, 2026
86,300M 2,100M 2,800M 2,300M 60.7 190 Sep 26, 2025 J-GAAP
YoY -8.2% -90.0% -86.8% -83.5% -83.4%